Guardant Health (NASDAQ:GH) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Tuesday, ValuEngine reports.

Several other research analysts also recently commented on GH. Zacks Investment Research raised Guardant Health from a “hold” rating to a “strong-buy” rating and set a $84.00 price objective for the company in a research note on Tuesday, November 12th. Cowen set a $110.00 target price on Guardant Health and gave the stock a “buy” rating in a research note on Wednesday, August 7th. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Friday, November 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $125.00 target price on shares of Guardant Health in a research note on Friday, November 8th. Finally, JPMorgan Chase & Co. raised their target price on Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Guardant Health has an average rating of “Buy” and an average price target of $107.60.

NASDAQ GH opened at $73.84 on Tuesday. The business has a fifty day moving average price of $72.25 and a 200 day moving average price of $81.37. Guardant Health has a one year low of $32.33 and a one year high of $112.21. The company has a market cap of $7.20 billion, a P/E ratio of -26.37 and a beta of 0.22.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.25. Guardant Health had a negative return on equity of 11.70% and a negative net margin of 40.99%. The firm had revenue of $60.85 million during the quarter, compared to the consensus estimate of $45.40 million. During the same period in the prior year, the company earned ($1.94) EPS. The firm’s revenue was up 180.4% compared to the same quarter last year. On average, research analysts predict that Guardant Health will post -0.88 EPS for the current fiscal year.

In other Guardant Health news, major shareholder Vision Fund (Aiv M1) Softbank sold 4,900,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $77.00, for a total value of $377,300,000.00. Also, VP Timothy P. Eckersley sold 2,364 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $118.24, for a total value of $279,519.36. Insiders sold a total of 5,024,854 shares of company stock valued at $386,916,261 over the last ninety days. Corporate insiders own 13.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA purchased a new position in shares of Guardant Health during the 2nd quarter worth $250,000. Coatue Management LLC purchased a new position in shares of Guardant Health during the 2nd quarter worth $103,251,000. Commonwealth Equity Services LLC grew its holdings in shares of Guardant Health by 47.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 5,812 shares of the company’s stock worth $501,000 after purchasing an additional 1,883 shares during the period. Advantage Investment Management LLC boosted its holdings in Guardant Health by 200.0% during the 2nd quarter. Advantage Investment Management LLC now owns 450 shares of the company’s stock valued at $39,000 after acquiring an additional 300 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Guardant Health by 102.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 83,405 shares of the company’s stock valued at $7,020,000 after acquiring an additional 42,193 shares during the period. Institutional investors and hedge funds own 78.19% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

See Also: What is meant by buying and selling pressure?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.